Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
BRCA-mut
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
HRD+, non BRCA-mut
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
Non BRCA-mut
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
Platinum sensitive
OVA-301
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
-
OVA-301
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
3
Olaparib
-
Placebo
Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (Phase II)Study 19
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA-mut
Study 19
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Cediranib
Chemotherapy
Platinum-based chemotherapy + placebo and placebo maintenance
Platinum-sensitive relapsed ovarian cancerICON 6
Gynaecological Malignancies
Ovarian Cancer
-
ICON 6
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
1
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 017
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
CheckMate 017
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 057
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate 057
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Erlotinib
-
Carboplatin gemcitabine
Locally advanced or metastatic NSCLC with EGFR activating mutationsOPTIMAL, CTONG-0802
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
OPTIMAL, CTONG-0802
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Erlotinib
-
Platinum-based chemotherapy doublet
Locally advanced or metastatic NSCLC with EGFR activating mutationsEURTAC
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
EURTAC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Gefitinib
-
Carboplatin + paclitaxel
Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase.IPASS
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
IPASS
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s)LUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysisLUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
5
Osimertinib
-
Platinum/pemetrexed
Osimertinib used as monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.AURA3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+ (T790M )
AURA3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Crizotinib
-
Chemotherapy
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)PROFILE 1007
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1007
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Crizotinib
-
Pemetrexed + cisplatin or carboplatin
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)PROFILE 1014
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1014
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
4
Pemetrexed
-
Placebo
As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
4
Pemetrexed
Cisplatin
Cisplatin + gemcitabine
In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
SCORE
F2c
4
Palliative care
Chemotherapy
Chemotherapy
First-line treatment stage IV NSCLC ECOG<2
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
SCORE
F2c
4
Pembrolizumab
-
Platinum-based chemotherapy
First line treatment of mNSCLC with tumour PD-L1 expression ≥50% TPS with no EGFR or ALK positive tumour mutationsKEYNOTE-24
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-24
A
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a/F1
5
A
Bevacizumab
Erlotinib
Erlotinib
In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutationsJO25567
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
JO25567
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
SCORE
F2b
2
Afatinib
-
Erlotinib
As monotherapy for the treatment of locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based ChTLUX - Lung 8
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
LUX - Lung 8
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
2
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
2
Ramucirumab
Docetaxel
Docetaxel + placebo
In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic NSCLC with disease progression after platinum-based chemotherapyREVEL
Thoracic Malignancies
Non-small-cell Lung Cancer
-
REVEL
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Necitumumab
Gemcitabine + cisplatin
Gemcitabine + cisplatin
Locally advanced or metastatic EGFR-expressing squamous NSCLC without prior ChTSQUIRE
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
SQUIRE
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Erlotinib
-
Placebo
Locally advanced or metastatic NSCLC with EGFR-activating mutations and stable disease after first-line ChTSATURN
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
SATURN
1
PRELIMINARY SCORE
OS
ADJUSTMENTS
SCORE
F2a
1
Imiquimod 5% cream
-
Placebo
For the topical treatment of small superficial basal cell carcinomas (cBCCs) in adults
Skin Cancers
Basal Cell Carcinoma
-
-
C
PRELIMINARY SCORE
pCR
ADJUSTMENTS
SCORE
F1
C
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.